Oura Agrees to Acquire Counsel Health for $625 Million
Oura has agreed to acquire Counsel Health, an AI-native primary care company (one built around AI from the outset rather than adding it later), for $625 million. The announcement is dated November 10, 2026, and the deal is expected to close before the end of 2027.
Counsel pairs a chat-based medical experience with access to licensed physicians. TechCrunch reports that Counsel raised a $25 million Series A, an early venture funding round, led by Andreessen Horowitz and GV. PitchBook estimates its total funding at $36 million. Seventy Counsel employees will join Oura as part of the transaction. Counsel CEO Muthu Alagappan will become Oura's chief clinical AI officer. After the acquisition, Counsel will continue to serve its existing and new enterprise partners, the businesses and organizations that license its service.
Counsel's service has been integrated into the Oura app since June. Oura's blog describes the acquisition as a way to bring physician-supervised care into the app, so that users can move from health insights to answers, often within minutes. Oura and Counsel plan to expand their partnership across preventative care, acute care, and specialty and chronic care. Neither the deal terms nor the expansion timeline beyond the closing window has been detailed.
The financial backdrop is substantial. Oura's revenue grew 153% year over year to $533 million for the quarter ended September 30. For fiscal year 2026, the company generated approximately $1.75 billion in revenue, up 92%. In October 2025, Oura reached an $11 billion valuation following a $900 million late-stage funding round. The company has postponed an IPO (initial public offering, the first sale of shares to the public) of up to $2.2 billion indefinitely, citing uncertainty in the IPO market, according to TechCrunch.
On the hardware side, Oura announced on November 9, 2026 that the Oura Ring 5 would be available online and in 1,000 Ulta Beauty stores starting this month.
The broader context here is where clinical judgment sits in a consumer wearable relationship. A ring collects continuous physiological data overnight and during the day. A chat interface interprets questions about that data, and a licensed physician supervises the answer. Each layer carries its own failure modes, from a model producing a confident but wrong reading to a clinician receiving a summary without the context behind it. How the supervision is structured, and how liability and data governance are divided between the consumer platform and the clinical provider, will matter more to users than the purchase price.
In my view, the more useful measure of this deal will be operational. The questions worth tracking through the 2027 closing are whether physician-supervised responses within the app reach users at the speed Oura describes, whether the enterprise commitments Counsel carries forward remain intact, and how the 70 incoming staff are integrated into a company whose core business has been hardware and subscriptions. The optimistic case is simple to state. If the handoff from a nightly readout to a clinician conversation works reliably, a wearable could shorten the distance between a data point and a useful medical answer for many people who now wait days or weeks for an appointment. Whether that happens will depend on execution rather than on the announcement itself.
